Abstract
Objective We sought to characterize C9orf72 expansions in relation to genetic ancestry and age at onset (AAO) and to use these measures to discriminate the behavioral from the language variant syndrome in a large pan-European cohort of frontotemporal lobar degeneration (FTLD) cases.
Methods We evaluated expansions frequency in the entire cohort (n = 1,396; behavioral variant frontotemporal dementia [bvFTD] [n = 800], primary progressive aphasia [PPA] [n = 495], and FTLD–motor neuron disease [MND] [n = 101]). We then focused on the bvFTD and PPA cases and tested for association between expansion status, syndromes, genetic ancestry, and AAO applying statistical tests comprising Fisher exact tests, analysis of variance with Tukey post hoc tests, and logistic and nonlinear mixed-effects model regressions.
Results We found C9orf72 pathogenic expansions in 4% of all cases (56/1,396). Expansion carriers differently distributed across syndromes: 12/101 FTLD-MND (11.9%), 40/800 bvFTD (5%), and 4/495 PPA (0.8%). While addressing population substructure through principal components analysis (PCA), we defined 2 patients groups with Central/Northern (n = 873) and Southern European (n = 523) ancestry. The proportion of expansion carriers was significantly higher in bvFTD compared to PPA (5% vs 0.8% [p = 2.17 × 10−5; odds ratio (OR) 6.4; confidence interval (CI) 2.31–24.99]), as well as in individuals with Central/Northern European compared to Southern European ancestry (4.4% vs 1.8% [p = 1.1 × 10−2; OR 2.5; CI 1.17–5.99]). Pathogenic expansions and Central/Northern European ancestry independently and inversely correlated with AAO. Our prediction model (based on expansions status, genetic ancestry, and AAO) predicted a diagnosis of bvFTD with 64% accuracy.
Conclusions Our results indicate correlation between pathogenic C9orf72 expansions, AAO, PCA-based Central/Northern European ancestry, and a diagnosis of bvFTD, implying complex genetic risk architectures differently underpinning the behavioral and language variant syndromes.
Glossary
- AAO=
- age at onset;
- bvFTD=
- behavioral variant frontotemporal dementia;
- FTLD=
- frontotemporal lobar degeneration;
- IFGC=
- International FTD Genetics Consortium;
- LOOCV=
- leave-one-out cross-validation;
- MND=
- motor neuron disease;
- PCA=
- principal components analysis;
- PNFA=
- progressive nonfluent aphasia;
- PPA=
- primary progressive aphasia;
- rc=
- repeat counts;
- SNP=
- single nucleotide polymorphism
Frontotemporal lobar degeneration (FTLD) refers to the second most common form of young-onset dementia after Alzheimer disease.1 The major clinical syndromes are behavioral variant frontotemporal dementia (bvFTD)2 or language dysfunctions, broadly called primary progressive aphasia (PPA); the latter is subdivided into semantic dementia or semantic variant PPA and progressive nonfluent aphasia (PNFA) or nonfluent/agrammatic variant PPA.2,3 FTLD can also occur together with motor neuron disease (MND) or amyotrophic lateral sclerosis in a continuous spectrum of phenotypes.4
In FTLD, repeat expansions in C9orf725 have been previously reported to occur in ∼25%6,–,10 of familial and ∼6%11 of sporadic cases (i.e., individuals with no clear familial history or genetic aetiology12). Several studies had shown high frequencies of pathogenic C9orf72 expansions in Northern vs Southern European patients (North–South axis), especially in historically isolated populations (such as the Finnish13,14), leading to the hypothesis that a Scandinavian founder might be at the basis of the spread of the C9orf72 expansion.15 Other studies (based on the geographic location of the recruiting sites) challenged the North–South axis concept, reporting a high frequency (∼25%) of pathogenic expansions in the Spanish population10 or implying to the existence of more than 1 risk haplotype.16,–,19
Patients with FTLD with abnormal C9orf72 repeat expansions exhibit marked phenotypic and pathologic heterogeneity, suggesting presence of additional (genetic and environmental) modifiers.20 Despite conflicting studies reporting either direct or inverse correlation between repeat length and age at onset (AAO), C9orf72 expansions have been suggested to act as a genetic modifier of AAO.16,21,–,24
We analyzed 1,396 FTLD cases gathered through the International FTD Genetics Consortium (IFGC) (ifgcsite.wordpress.com/) phase III initiative, aiming at (1) characterizing C9orf72 expansions in relation to genetic ancestry and AAO and (2) assessing the usefulness of these measures in discriminating the behavioral from the language variant syndrome.
Methods
Standard protocol approvals, registrations, and patient consents
Each contributing site obtained written informed consent from all patients to be part of extended genetic studies; the current study is approved under institutional review board approval 9811/001.
Cohort, clinical phenotyping
FTLD cases were collected between 2016 and 2018 (within the IFGC phase III project [ifgcsite.wordpress.com/ongoing-projects/]). The samples were recruited by clinicians and research groups who are part of the IFGC network and based in Italy, Spain, Germany, the Netherlands, Belgium, the United Kingdom, Sweden, Norway, Slovenia, or the United States (supplementary table 1, doi.org/10.5522/04/12418157). Patients were diagnosed at each contributing site (supplementary table 2, doi.org/10.5522/04/12418157) in a harmonized fashion according to international consensus criteria such as those of Neary et al.2 (for FTLD), Rascovsky et al.25 (for bvFTD), Gorno-Tempini et al.3 (for PPA [semantic dementia or PNFA]), and Strong et al.4 (for FTLD-MND).
Genotyping, C9orf72 repeat expansions, and analysis cohorts
A total of 1,454 cases were successfully genotyped by means of the NeuroArray26 on the Illumina Infinium platform. Genotypes were used to inform on population substructure via standard principal components analysis (PCA) (supplementary figure 1, doi.org/10.5522/04/12418157), which led to the exclusion of 44 population outliers, and allowed us to address population substructure within the cohort (we identified 2 distinct [Nordic and Mediterranean] clusters; supplementary figure 2, doi.org/10.5522/04/12418157). We also assessed cryptic relatedness and excluded 14 first- or second-degree related individuals, leaving a cohort of 1,396 cases (group 0)—for which C9orf72 expansion status (i.e., presence/absence of pathogenic expansions) was known—for analyses. Frequencies of pathogenic expansions were assessed in group 0 and further analyses were performed in (1) 1,295 cases (group 1: n = 800 bvFTD and n = 495 PPA) with known C9orf72 expansion status; (2) 1,179 cases (group 2; n = 756 bvFTD and n = 423 PPA) with known C9orf72 expansion status and AAO data available; and (3) 734 cases (group 3; n = 462 bvFTD and n = 272 PPA) with AAO and repeat counts (rc; screened via repeat-primed PCR) (see references 27 and 28; supplementary Methods and supplementary figure 3, doi.org/10.5522/04/12418157; and figure 1A).
(A) Cohorts. (B) Analysis workflow. K-fold regression model. AAO = age at onset; ANOVA = analysis of variance; bvFTD = behavioral variant frontotemporal dementia; FTLD = frontotemporal lobar degeneration; logistic/cluster = logistic regression using cluster as covariate; logistic/PC1 = logistic regression using PC1 as covariate; LOOCV = leave-one-out cross-validation regression model; MND = motor neuron disease; PPA = primary progressive aphasia.
Statistical analyses
We first assessed the frequency of pathogenic expansions in the entire cohort (group 0). The information on presence/absence of expansions was used as a binary variable (0 = absence of expansion; 1 = presence of expansion). We then investigated differences in the frequencies of pathogenic expansions across bvFTD and PPA and the Nordic and Mediterranean clusters in group 1 (Fisher exact test) and in group 3 (logistic regression); in the latter, we used rc as a categorical variable (using no, short, intermediate, and long as factor levels) considering the following 4 categories: no expansions (rc = 2/3), short expansions (4 ≤ rc ≤ 8), intermediate expansions (9 ≤ rc ≤ 24), and long expansions (rc ≥ 25), the latter representing expansions in the pathogenic range (see references 10 and 22, supplementary Methods, and supplementary figure 3, doi.org/10.5522/04/12418157).
We then evaluated association between AAO and syndrome, genetic ancestry, and expansions (i.e., presence/absence used as a binary variable; see above) alone and with genetic ancestry as a covariate in group 2 (t test and logistic regression) and in group 3 (t test, analysis of variance with Tukey post hoc test, and logistic and linear mixed-effects model). In the latter case, we used rc as a categorical variable (see above).
Finally, we sought to build a model to predict syndrome (bvFTD vs PPA) using (1) presence/absence of pathogenic expansions (as binary variable [see above] for group 2) or (2) rc (as categorical variable [see above] for group 3), ancestry as binary variable, and AAO as continuous variable using logistic regression models (i.e., the leave-one-out cross-validation [LOOCV] and the K-fold models). A summary of the analyses workflow can be found in figure 1B.
All analyses were performed using R studio (version 3.6.0, studio version 1.2.1335).
C9orf72 locus risk haplotype
Twenty (rs1110264, rs1110155, rs2150336, rs1161680, rs2589054, rs1822723, rs4879515, rs895023, rs868856, rs1977661, rs903603, rs12349820, rs10122902, rs2282241, rs1948522, rs1982915, rs2453556, rs702231, rs696826, and rs247751) of the original 42 single nucleotide polymorphisms (SNPs) constituting the (Finnish) risk haplotype29 were available on the NeuroArray.26 We filtered out 7 markers in order to keep 13 informative SNPs (rs1822723, rs4879515, rs868856, rs1977661, rs903603, rs10122902, rs2282241, rs1948522, rs1982915, rs2453556, rs702231, rs696826, and rs2477518) matching 13 of the 20 used in Mok et al.15 We evaluated the proportion of cases carrying at least 1 risk allele (as in Mok et al.15) for each marker assessing expansion vs nonexpansion carriers (with/without ancestry stratification).
Data availability
All data generated or analyzed during this study are included in this published article and supplementary files 1 and 2 at doi.org/10.5522/04/12418157.
Results
C9orf72 expansions frequency and syndromes
We assessed the frequency of pathogenic expansions in the entire cohort and across the different syndromes in the group 0 cases (figure 1). Four percent of all cases (56/1,396 [4%]) carried pathogenic expansions. These were most frequent in FTLD-MND (12/101 [11.9%]) followed by bvFTD (40/800 [5%]) and PPA (4/495 [0.8%]). The higher prevalence of pathogenic expansions in bvFTD vs PPA was statistically significant (Fisher exact test: p = 2.17 × 10−5; OR 6.4; 95% CI 2.31–24.99, table 1). We further explored this finding in the group 3 cases using logistic regression to assess association between expansion length (represented by 4 rc factor levels: short, intermediate, and long expansions, tested against no expansions) and syndromes (bvFTD vs PPA). Expansion length discriminated bvFTD from PPA with a trend that was significant in the intermediate (p = 4.7 × 10−2; OR 1.6; CI 0.0061 [2.5%]–0.94 [97.5%]) and long (p = 1.9 × 10−3; OR 7.2; CI 0.86 [2.5%]–3.45 [97.5%]) rc ranges (with a ∼90% probability of a bvFTD diagnosis supported by the latter; supplementary table 3, doi.org/10.5522/04/12418157).
Frequency of expansion carriers in the entire cohort and by syndrome
C9orf72 expansions (and rc) and genetic ancestry
We performed PCA (PC1 vs PC2, supplementary figure 2A; PC1 vs PC3, supplementary figure 2B, doi.org/10.5522/04/12418157) to cluster the group 1 cases based on their genetic makeup. There were 2 major clusters: cluster 1 (Mediterranean) included most of the cases (439/500 [87.8%]) recruited from Southern European sites (Italy and Spain); cluster 2 (Nordic) included most of the cases (627/795 [78.8%]) recruited from Central and Northern European sites (Belgium, the Netherlands, Germany, the United Kingdom, Norway, and Sweden). Samples recruited from Eastern European (Slovenia) and North American sites distributed across both clusters, although with a higher prevalence within cluster 2 (167/795 [21%]) vs cluster 1 (42/500 [8.4%]).
We observed a significantly higher prevalence of pathogenic expansions in the Nordic (35/795 [4.4%]) vs the Mediterranean (9/500 [1.8%]) cluster (Fisher exact test: p = 1.1 × 10−2; OR 2.5; CI 1.17–5.99, table 2). We further evaluated this finding in the group 3 cases using logistic regression to assess association between expansion length (see above) and genetic ancestry. Expansion length discriminated the Nordic from Mediterranean cluster with a trend that was significant in the intermediate (p = 9.7 × 10−4, OR 2.2; CI 0.32 [2.5%]–1.25 [97.5%]) and long (p = 4.7 × 10−4, OR 9.3; CI 1.12 [2.5%]–3.7 [97.5%]) rc ranges (with a ∼90% probability of Nordic ancestry supported by the latter; supplementary table 4, doi.org/10.5522/04/12418157).
Frequency of expansion carriers in the Nordic and Mediterranean clusters
Provided differences in syndromes prevalence and distribution across the Nordic and Mediterranean clusters—bvFTD (469/795 [59%] vs 331/500 [66.2%]) and PPA (326/795 [41%] vs 169/500 [33.8%]), respectively (supplementary table 5, doi.org/10.5522/04/12418157)—we analyzed the distribution of pathogenic expansions across syndromes and clusters. Stratified Fisher exact test showed significant differences in the distribution of the pathogenic expansions between bvFTD and PPA in the Nordic (but not the Mediterranean) cluster (p = 1 × 10−4; OR 7.87; 95% CI 2.43–40.52), and between the Nordic and the Mediterranean clusters for the bvFTD (but not PPA) syndrome (p = 1.9 × 10−2; OR 2.95; 95% CI 1.31–7.52), suggesting that ancestry (Nordic) and syndrome (bvFTD) are independently associated with pathogenic expansions (table 3).
Stratified Fisher exact tests comparing prevalence of pathogenic expansions across behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA) and the Nordic and Mediterranean clusters
C9orf72 repeat expansions (and counts [rc]) and AAO
We assessed AAO in the group 2 cases (figure 1). Mean AAO was significantly different between the bvFTD (61.7) and PPA (64) syndromes (t test: p = 1.86 × 10−5; CI −3.34 to −1.25) and the Nordic (61.3) and Mediterranean (64.3) clusters (t test: p = 1.16 × 10−7; CI 1.86–4.03) (figure 2A and supplementary table 6, A and B, doi.org/10.5522/04/12418157). We then assessed the relationship between pathogenic expansions and AAO via logistic regression. First, we identified a significant correlation between a decrease in AAO and presence of pathogenic expansions (p = 7.7 × 10−4; R2 = 0.008; CI −8.05 [2.5%] to −2.13 [97.5%]). When we included genetic ancestry in the model, we observed a significant correlation with a decrease in AAO, with no difference in using either cluster (p = 2.3 × 10−3; CI −7.5 [2.5%] to −1.63 [97.5%] for pathogenic expansions; p = 2.3 × 10−7; CI −3.9 [2.5%] to −1.77 [97.5%] for cluster; R2 = 0.03) or PC1 (p = 2.1 × 10−3; CI −7.5 [2.5%] to −1.66 [97.5%] for pathogenic expansions; p = 6.4 × 10−7; CI 30.1 [2.5%]–68.9 [97.5%] for PC1; R2 = 0.028) as covariate and an almost 4-fold goodness of fit increase (supplementary table 7, A–C, doi.org/10.5522/04/12418157). Of note, when comparing the 2 regression models (with/without genetic ancestry as covariate) through the log-likelihood R2 ratio test, the difference (between the 2 models) appeared not to be due to chance (p < 10−12) (supplementary table 7, B and C, doi.org/10.5522/04/12418157).
(A) AAO in the group 2 cases. Mean AAO behavioral variant frontotemporal dementia (bvFTD) (61.7) and primary progressive aphasia (PPA) (64) (t test: p = 1.86 × 10−5; confidence interval [CI] −3.34 to 1.25); mean AAO Nordic (61.3) and Mediterranean (64.3) clusters (t test: p = 1.16 × 10−7; CI 1.86–4.03). (B) AAO in the group 3 cases. Mean AAO bvFTD (61.7) and PPA (63.5) (t test: p = 9.1 × 10−3; CI −3.11 to 0.44); mean AAO Nordic (60.9) and Mediterranean (64.6) (t test: p = 2.1 × 10−7; CI 2.32–5.09). (C) AAO in the group 3 cases. Mean AAO for both no and short expansions (63.2), for intermediate expansions (61), and for long expansions (58) evaluated via analysis of variance test.
We further evaluated the relationship between expansion length (represented by 4 rc factor levels—short, intermediate, and long expansions, tested against no expansions) and AAO in the group 3 cases (figure 1). First, we independently analyzed association between AAO and (1) genetic ancestry—mean AAO 60.9 and 64.6 in the Nordic and Mediterranean cluster, respectively (t test: p = 2.1 × 10−7; CI 2.32–5.09; supplementary table 8A, doi.org/10.5522/04/12418157); (2) syndrome—mean AAO 61.7 and 63.5 in the bvFTD and PPA syndromes, respectively (t test: p = 9.1 × 10−3; CI −3.11 to −0.44; supplementary table 8B, doi.org/10.5522/04/12418157), and (3) expansion length—mean AAO 63.2 for both no and short expansions, 61 for intermediate expansions, and 58 for long expansions (analysis of variance p = 3.6 × 10−2; CI −10.2 to −0.23 for long vs no expansions) (supplementary table 8D, figure 2B and C: doi.org/10.5522/04/12418157). We then assessed the relationship between expansion length (see above) and AAO via logistic regression. First, we identified a significant correlation between a decrease in AAO and both intermediate and long expansions (p = 4 × 10−2; CI −4.36 [2.5%] to −0.96 [97.5%] for intermediate and p = 7 × 10−3; CI −9.05 [2.5%] to −1.43 [97.5%] for long expansions; R2 = 0.017) (supplementary table 9A, doi.org/10.5522/04/12418157). When we included genetic ancestry in the model, we observed a significant correlation with a decrease in AAO, no difference in using either cluster (p = 4.7 × 10−2; CI −7.65 [2.5%] to −0.05 [97.5%] for long vs no expansion; p = 2.38 × 10−6; CI −4.73 [2.5%] to −1.97 [97.5%] for cluster; R2 = 0.045) or PC1 (p = 5.98 × 10−2; CI −7.5 [2.5%] to 0.14 [97.5%] for long vs no expansion; p = 1.2 × 10−6; CI 39.8 [2.5%] –92.9 [97.5%] for PC1; R2 = 0.047) as covariate and an almost 3-fold goodness of fit increase (supplementary table 9, A–C, doi.org/10.5522/04/12418157). Of note, when comparing the 2 regression models (with/without genetic ancestry as covariate) through the log-likelihood R2 ratio test, the difference (between the 2 models) appeared not to be due to chance (p < 10−12) (supplementary table 9, B and C, doi.org/10.5522/04/12418157). These findings were further supported by nonlinear mixed-effects model regression using genetic ancestry as random effect covariate (for long vs no expansion; see supplementary table 10, doi.org/10.5522/04/12418157).
C9orf72 locus risk haplotype
All of the risk alleles for the 13 markers—shortest informative stretch of the original risk haplotype15,29 available to us—were seen in (1) 40/56 (71.4%) expansion carriers vs 380/1,340 (28.4%) nonexpansion carriers in the entire cohort; (2) 33/47 (70.2%) expansion carriers vs 228/826 (27.6%) nonexpansion carriers in the Nordic cluster; and (3) 7/9 (77.8%) expansion carriers vs 152/514 (29.6%) nonexpansion carriers in the Mediterranean cluster. Comparing the proportion of risk allele carriers (expansion vs nonexpansion carriers) for each single marker, 5/13 markers (rs4879515, rs868856, rs903603, rs2282241, rs2453556) were significant in the Nordic cluster, and none in the Mediterranean cluster (supplementary figure 4, doi.org/10.5522/04/12418157). Rs2477518 showed variable frequencies for the risk allele (T) across expansion vs nonexpansion carriers (and the 2 clusters), thus making this most probably a negligible marker within this stretch, as hinted previously.15,17 Rs3849942, previously suggested as a surrogate marker for the risk haplotype,15 was not among the SNPs available to us. We used rs868856, displaying strongest linkage disequilibrium with rs3849942 (D' = 0.96; R2 = 0.7; ldlink.nci.nih.gov/), as informative proxy: the risk allele segregated differently across expansion vs nonexpansion carriers in the Nordic and Mediterranean cluster (as for rs2453556), possibly suggesting these 2 as the most conserved markers of the original risk haplotype across populations in expansion carriers (highlighted in blue in supplementary figure 4, doi.org/10.5522/04/12418157).
Syndrome prediction
We then sought to build a model to predict syndrome (bvFTD vs PPA) and assess its accuracy. We analyzed both groups 2 and 3 cases using expansion status (presence/absence of expansion for group 2 and the 4 rc factor levels for group 3 [see Methods]), genetic ancestry (using either cluster or PC1) as binary variables, and AAO as a continuous variable in logistic regression models. We observed an accuracy of ∼0.64 (group 2; supplementary table 11, doi.org/10.5522/04/12418157) and ∼0.62 (group 3; supplementary table 12, doi.org/10.5522/04/12418157) in predicting bvFTD; there were no differences in the outcome when using either cluster or PC1 as covariates in both (LOOCV and K-fold) models.
Discussion
This study aimed to characterize C9orf72 expansions in relation to genetic ancestry and AAO and to assess the usefulness of these measures in discriminating the behavioral from the language variant syndrome in a large pan-European cohort of 1,396 FTLD cases.
To our knowledge, the current work is unique in that, prior to characterizing the expansions, we excluded population-substructure bias using genome-wide genotyping data to cluster the cases on the basis of their genetic makeup. After PCA, we identified 2 distinct clusters including samples with geographic ancestry corresponding to Southern Europe (Mediterranean cluster) and Central/Northern Europe (Nordic cluster). Our analyses not only showed that patients from the Nordic cluster presented significantly higher frequency of pathogenic C9orf72 expansions compared to the Mediterranean cluster, but also that a core stretch of markers (n = 8) of the Finnish risk haplotype29 appeared to be conserved across the Nordic expansion carriers, whereas there was a similar tendency for (just) 2 of such markers in the Mediterranean expansion carriers. Several studies had shown high frequencies of long C9orf72 expansions in Northern vs Southern European patients (North–South axis).13,–,15 Other studies (based on the geographic location of the recruiting sites) challenged the North–South axis concept,10 or the founder effect implying the existence of more than 1 risk haplotype.16,–,19 All this taken together, our current data appear to support the North–South axis hypothesis and suggest that rearrangements (and instability)16,19 at the C9orf72 locus might have occurred, reducing the level of conservation of the original risk haplotype across the European population.
We found pathogenic expansions in ∼4% of all cases and that the proportion of expansion carriers was significantly higher in bvFTD compared to PPA. The fact that we overall identified significant association between pathogenic expansions and a diagnosis of bvFTD and Central/Northern European ancestry—findings in line with previous reports8,10,13,20,30,–,34—suggests that C9orf72 expansions might serve as useful genetic fingerprint to define subpopulations of FTLD (figure 3). Of note, we observed a trend of association with syndrome (bvFTD) and genetic ancestry (Central/Northern European) already supported by the intermediate repeat counts (9 ≤ rc ≤ 24) category. This appears in line with previous reports suggesting that individuals with 7–24 alleles might have an increased risk to convert to carriers of pathologic repeat expansions10,22 and may, altogether, be useful information in the context of diagnostics.
Despite some previous conflicting reports of direct (or inverse) correlation between C9orf72 expansions and AAO,16,21,23 we (as others22,24) found a significant inverse correlation between C9orf72 expansion length and AAO. In addition, and interestingly, our data also indicate that Central/Northern European genetic ancestry contributes to a decreased AAO (independently from the expansions), possibly implying a more complex genetic signature (or architecture), and subsequently molecular mechanisms, underpinning this feature. Clearly, disease mechanisms that involve C9orf72 expansion length and AAO are complex, thus it is likely that additional factors might further modulate their relationship and effect on the phenotype (see also Babić Leko et al.5).
While using expansion length, genetic ancestry, and AAO in a regression model to discriminate behavioral from language variant subtypes, we found that such measures supported a prediction of bvFTD with 64% accuracy.
Our results have a number of implications. First, provided that significant variation exists in the genetic architecture of the Caucasian population,35 genetic variability characterizing and differentiating Nordic vs Mediterranean subjects (such as in the case of our cohort) might influence predisposition to harboring longer repeat expansions. In other repeat expansion diseases—e.g., Huntington disease or other microsatellite diseases, including myotonic dystrophy and spinocerebellar ataxias35—the presence of specific haplogroups in Western European populations occurs with a manifold increase in prevalence of repeats compared to other ethnic groups and populations.36 Second, different genetic risk architectures underpinning different (and possibly genetically more homogeneous) subpopulations of patients may exist within the FTLD population.
In a nutshell, our results imply that a significantly higher proportion of FTLD cases, with Nordic rather than Mediterranean genetic ancestry, is likely to develop bvFTD in presence of intermediate and long (pathogenic) expansions, whereas long (pathogenic) expansions are (almost) negligible in PPA, regardless of ancestry. Clearly, multiple factors including genetic heterogeneity, epigenetic changes, ethnicity, as well as environmental factors and habits that may subsist within and across multicultural cohorts, all together, contribute to disease predisposition, onset, and progression.22,37,38 These concepts, reinforced by our study, warrant further characterization of genetic, environmental, and additional clinical measures to fine-tune models able to predict disease outcome to complement diagnostic criteria, and possibly assist in the identification of informative cohorts for tailored clinical trials and the development of effective personalized therapies.
Study funding
R. Ferrari and B. Costa are supported by funding from the Alzheimer's Society (grants 284 and 447). V. Alvarez and M. Menendez-Gonzalez are supported by the Fondos Feder (grant PI 15/00878). O. Andreassen is supported by the Research Council of Norway (grant 223273), Norwegian Health Association, and the KG Jebsen Stiftelsen. L. Benussi, R. Ghidoni, G. Rossi, and F. Tagliavini are supported by the Italian Ministry of Health–Ricerca Corrente. G. Bråthen and R. Ghidoni are supported by the Italian Ministry of Health (grant RF-2016-02361492). D. Blackburn is supported by the Sheffield Biomedical Research Centre. L. Bernardi is supported by the National Institute for Health Research Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia (NIHR, grant RG64473). T.E. Cope is supported by the Association of British Neurologists; the recruitment and clinical characterization of research participants at Washington University were supported by NIH (grants R01AG044546, RF1AG053303, R01AG058501, U01AG058922, P50 AG05681, P01 AG03991, and P01 AG026276). F. Frangipane is supported by ONLUS Lamezia Terme. C. Graff is supported by grants from JPND Prefrontals Swedish Research Council (VR) 529-2014-7504, Swedish Research Council (VR) 2015-02926, Swedish Research Council (VR) 2018-02754, Swedish FTD Initiative-Schörling Foundation, Swedish Brain Foundation, Swedish Alzheimer Foundation, Stockholm County Council ALF, Karolinska Institutet Doctoral Funding, and StratNeuro, Swedish Demensfonden. M. Gallo is supported by the NIH (grant AG054519). M. Gallucci, E. Scarpini, J.C. Thompson and V.M. Van Deerlin are supported by the NIH (grant AG017586, and P30 AG10124 and U01 AG062418). J. Hardy and P.A. Lewis are supported by an MRC Programme grant (MR/N026004/1). J. Hardy is supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK, Wellcome Trust (award 202903/Z/16/Z), Dolby Family Fund, National Institute for Health Research University College London Hospitals Biomedical Research Centre, BRCNIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust, and University College London. R. Maletta is supported by the Associazione per la Ricerca Neurogenetica. B. Miller is supported by the NIH (grants P50-AG023501 and P01-AG1972403) (BLM). C.M. Morris is supported by the Newcastle Brain Tissue Resource, the UK Medical Research Council (grant G0400074), the NIHR Newcastle Biomedical Research Centre awarded to the Newcastle upon Tyne NHS Foundation Trust and Newcastle University, and a grant from the Alzheimer's Society and Alzheimer's Research UK as part of the Brains for Dementia Research Project. B. Nacmias and S.B. Sando are supported by the Ricerca di Ateneo 2019. E. Rogaeva is supported by the Canadian Consortium on Neurodegeneration in Aging. B. Rogelj is supported by grants from the Slovenian Research Agency (grants P4-0127, J3-8201, J3-9263). J. van Rooij is supported by the Wellcome Trust (grant 103838), by the Medical Research Council (grant number SUAG004/91365), and by the National Institute for Health Research Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia (NIHR, grant RG64473). A. Rendina is supported by the Innovative Medicines Initiative 2 Joint Undertaking, which receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA (grant 115975), by Acción Estratégica en Salud integrated in the Spanish National R + D + I Plan (grants PI13/02434 and PI16/01861), by ISCIII (Instituto de Salud Carlos III) Subdirección General de Evaluación, and by the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de Hacer Europa). M. Boada and A. Ruiz are funded by Fundación bancaria La Caixa and Grifols SA (GR@ACE project). R. Sanchez-Valle is funded by the Spanish National Institute of Health Carlos III (ISCIII) under the aegis of the EU Joint Programme–Neurodegenerative Disease Research (JPND) (grant AC14/00013) and Fundacio Marato de TV3 (20143810) (RSV). J.Q. Trojanowski is supported by the NIH (grant AG09215). C. Van Broeckhoven and J. Van der Zee are supported by the Flemish Government initiated Impulse Program on Networks for Dementia Research (VIND) and the Methusalem Excellence Program, by the Research Foundation Flanders (FWO), and by the University of Antwerp Research Fund (Belgium). M.L. Waldö is supported by the Elly Berggren Foundation. J. Yokoyama is funded by NIA K01 AG049152.
Disclosure
C. Cruchaga receives research support from Biogen, EISAI, Alector, and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. C. Cupidi is a member of the advisory board of ADx Healthcare and Vivid Genomics. B. Costa, C. Manzoni, M. Bernal-Quiros, D.A. Kia, M. Aguilar, I. Alvarez, V. Alvarez, O. Andreassen, M. Anfossi, S. Bagnoli, L. Benussi, L. Bernardi, G. Binetti, D. Blackburn, M. Boada, B. Borroni, L. Bowns, G. Bråthen, A.C. Bruni, H.-H. Chiang, J. Clarimon, S. Colville, M.E. Conidi, T.E. Cope, C. Cruchaga, M.E. Di Battista, J. Diehl-Schmid, M. Diez-Fairen, O. Dols-Icardo, E. Durante, D. Flisar, F. Frangipane, D. Galimberti, M. Gallo, M. Gallucci, R. Ghidoni, C. Graff, J.H. Grafman, M. Grossman, J. Hardy, I. Hernández, G.J.T. Holloway, E.D. Huey, I. Illán-Gala, A. Karydas, B. Khoshnood, M.G. Kramberger, M. Kristiansen, P.A. Lewis, A. Lleó, G.K. Madhan, R. Maletta, A. Maver, M. Menendez-Gonzalez, G. Milan, B. Miller, M.O. Mol, P. Momeni, S. Moreno-Grau, C.M. Morris, B. Nacmias, C. Nilsson, V. Novelli, L. Öijerstedt, A. Padovani, S. Pal, Y. Panchbhaya, P. Pastor, B. Peterlin, I. Piaceri, S. Pickering-Brown, Y.A.L. Pijnenburg, A.A. Puca, I. Rainero, A. Rendina, A.M.T. Richardson, E. Rogaeva, B. Rogelj, S. Rollinson, G. Rossi, C. Rossmeier, J.B. Rowe, E. Rubino, A. Ruiz, R. Sanchez-Valle, S.B. Sando, A.F. Santillo, J. Saxon, E. Scarpini, M. Serpente, N. Smirne, S. Sorbi, E. Suh, F. Tagliavini, J.C. Thompson, J.Q. Trojanowski, V.M. Van Deerlin, J. Van der Zee, C. Van Broeckhoven, J. van Rooij, J.C. Van Swieten, A. Veronesi, E. Vitale, M.L. Waldö, C. Woodward, J. Yokoyama, V. Escott-Price, J.M. Polke, and R. Ferrari report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
Acknowledgment
The authors thank the patients and their families and the IFGC (ifgcsite.wordpress.com/) phase III network.
Appendix 1 Authors
Appendix 2 Coinvestigators
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
International FTD-Genetics Consortium (IFGC) coinvestigators are listed at links.lww.com/WNL/B240.
The Article Processing Charge was funded by MRC and Wellcome Trust.
- Received April 15, 2020.
- Accepted in final form August 12, 2020.
- Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Letters: Rapid online correspondence
- Reader response: C9orf72, AAO and ancestry help discriminating behavioural from language variants in FTLD cohorts
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg